All In Biotech

Drug Trial Radar · NCT06465199

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 265 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

265

Planned (sponsor's estimate)

Start

May 13, 2026

Primary completion

May 2033

Study completion May 2035

Sponsor

Lead sponsor
Milton S. Hershey Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aminex Therapeutics, Inc.; Penn State University
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 26 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of AMXT 1501 in combination with DFMO * Test the safety and tolerability of AMXT 1501 in combination with DFMO * To determine the activity of study treatments chosen based on: * How each subject responds to the study treatment * How long a subject lives without their disease returning/progressing

Conditions

  • Atypical Teratoid/Rhabdoid Tumor
  • Embryonal Tumor With Multilayered Rosettes
  • Ewing Sarcoma
  • Diffuse Intrinsic Pontine Glioma
  • Osteosarcoma
  • Neuroblastoma
  • DIPG Brain Tumor

Interventions

  • Eflornithine (DFMO)Drug

    Oral DFMO capsules

  • AMXT 1501 DicaprateDrug

    Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 28 days
  2. Phase II- Number of Cohort 1 participants with progression free survival (PFS) during studyTime frame: 2 years plus 5 years follow up
  3. Phase II- Number of Cohort 2-4 participants with progression free survival (PFS) during studyTime frame: 2 years plus 5 years follow up

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama/Children's of Alabama

    Birmingham, Alabama · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Connecticut Children's Hospital

    Hartford, Connecticut · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • St. Joseph's Children's Hospital

    Tampa, Florida · Recruiting

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii · Recruiting

  • Children's Mercy Hospitals and Clinics

    Kansas City, Kansas · Recruiting

  • Helen DeVos Children's Hospital

    Grand Rapids, Michigan · Recruiting

  • Cardinal Glennon Children's Medical Center

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Penn State Milton S. Hershey Medical Center and Children's Hospital

    Hershey, Pennsylvania · Recruiting

  • Monroe Carrell Jr. Children's Hospital at Vanderbilt

    Nashville, Tennessee · Recruiting

  • Dell Children's Blood and Cancer Center

    Austin, Texas · Recruiting

  • Children's Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.